Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TDF · 1 trial · 1 indication
AUC(0-t) of single dose
AUC(0-τ) during steady state
| Arm | Type | Description |
|---|---|---|
| TDF tablets | EXPERIMENTAL | Tenofovir disoproxil fumarate tablets |
| Name | Type | Description |
|---|---|---|
| TDF tablets | DRUG | White, almond-shaped, film-coated tablets, one side with the markings "GILEAD" and "4331" |
Inclusion Criteria: * Healthy, as determined by a responsible and experienced physician * Male or female between 18 and 45 years of age * Body weight \>50 kg (110 lbs) for males or \>45 kg (100 lbs) for females, and body mass index (BMI) between 19.0 and 24.0 kg/m2 Exclusion Criteria: * Positive ...
TDF is a small molecule being developed for the treatment of chronic Hepatitis B. It is currently in Phase 1 clinical development, meaning it is investigational and has not yet been approved for this indication.
TDF is being developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. The drug is in Phase 1 clinical development for chronic Hepatitis B.
TDF is in Phase 1 clinical development. It has completed one Phase 1 trial, and no active trials are currently listed. The drug remains investigational and has not been approved for any use.
TDF has one completed clinical trial, NCT01480622, titled 'Pharmacokinetic (PK) Profiles of Tenofovir Disoproxil Fumarate (TDF) 300 mg in Healthy Chinese Subjects.' This Phase 1 study enrolled 14 participants and was conducted in China.
Yes, TDF is an abbreviation for Tenofovir Disoproxil Fumarate. The completed clinical trial NCT01480622 explicitly studies TDF 300 mg, confirming that TDF and Tenofovir Disoproxil Fumarate refer to the same drug.